Cresco Labs: Consensus First Quarter 2021 Estimates

Cresco Labs (CSE: CL) announced that they will be reporting their first quarter financials before market open on March 27th. Analysts have a consensus C$23.36 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating, 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$34 price target, and the lowest target comes from Echelon Wealth with a C$19 price target.

Fourteen analysts have revenue estimates for the third fiscal quarter. The mean between all 14 is U$211.76 million; this number has been revised upwards from U$209.46 million at the start of the year. The highest revenue estimate currently sits at $223 million, while the lowest comes in at a U$193 million estimate.

Eigtht analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 53.05%, with this number being revised slightly higher from 49.55% at the start of the year. Street high goes to BTIG with a 56% estimate and the lowest sits at 50% from Echelon.

Onto EBITDA estimates, there are currently 11 analysts who have third quarter EBITDA estimates. The mean is currently U$64.75 million, with this number being revised downwards from U$69.63 million at the start of the year. Street high goes to Haywood with a U$73.90 million EBITDA estimate and the lowest being from Echelon Wealth with a U$56.90 million estimate..


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Silver47 Completes Property-Wide Geochemical, Rock Sampling Program At Adams Plateau, Identifies Numerous Targets

Altamira Gold Identifies Presence Of Second Mineralized Porphyry Body At Cajueiro

Related News

Curaleaf: Consensus Estimate Falls To $20.18 After Weak Guidance

On March 3rd, Curaleaf Holdings, Inc. (CSE: CURA) reported its fourth quarter and full year...

Friday, March 11, 2022, 04:20:00 PM

Trulieve Sees Consensus Price Target Tumble After Cutting Guidance

Trulieve Cannabis (CSE: TRUL) reported its second quarter financial results on Wednesday. The company announced...

Thursday, August 11, 2022, 04:39:00 PM

Medipharm Labs: Canaccord Drops Target To Just $0.10

On May 16, Medipharm Labs (TSX: LABS) reported its first quarter financial results. The company...

Tuesday, May 24, 2022, 11:37:00 AM

Karora: Haywood Reiterates Ratings After Three Year Guidance Announcement

On June 28th, Karora Resources Inc. (TSX: KRR) announced its three-year production guidance, whereby they...

Wednesday, June 30, 2021, 04:53:00 PM

Equinox Gold: Mercedes Mine Sale Was “A Favourable Sale Price For A Non-Core Asset”

On December 17th, Equinox Gold (TSX: EQX) announced that they reached an agreement to sell...

Sunday, December 26, 2021, 02:14:00 PM